Literature DB >> 22590484

Exemestane in the prevention setting.

Jennifer Keating Litton1, Therese B Bevers, Banu K Arun.   

Abstract

Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.

Entities:  

Keywords:  aromatase inhibitors; breast cancer; exemestane; prevention

Year:  2012        PMID： 22590484      PMCID： PMC3349074          DOI： 10.1177/1758834012438214

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  35 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

Review 2.  Aromatase inhibitors for breast cancer: lessons from the laboratory.

Authors:  Stephen R D Johnston; Mitch Dowsett
Journal:  Nat Rev Cancer       Date:  2003-11       Impact factor: 60.716

3.  Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Authors:  Maryam B Lustberg; Stephen P Povoski; Weiqiang Zhao; Rebecca M Ziegler; Yasuro Sugimoto; Amy S Ruppert; Amy M Lehman; Donna R Shiels; Ewa Mrozek; Bhuvaneswari Ramaswamy; Rachel M Layman; Robert W Brueggemeier; Charles L Shapiro
Journal:  Clin Breast Cancer       Date:  2011-05-19       Impact factor: 3.225

4.  The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.

Authors:  Peyman Hadji; Lina Asmar; Johanna G H van Nes; Thomas Menschik; Annette Hasenburg; Joachim Kuck; Johan W R Nortier; Cornelis J H van de Velde; Stephen E Jones; May Ziller
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-18       Impact factor: 4.553

Review 5.  A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer.

Authors:  M Beresford; I Tumur; J Chakrabarti; J Barden; N Rao; A Makris
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-12-04       Impact factor: 4.126

6.  High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

Authors:  S Kvinnsland; G Anker; L Y Dirix; J Bonneterre; A M Prove; N Wilking; J P Lobelle; O Mariani; E di Salle; A Polli; G Massimini
Journal:  Eur J Cancer       Date:  2000-05       Impact factor: 9.162

7.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

Authors:  Robert E Coleman; Linda M Banks; Samia I Girgis; Lucy S Kilburn; Eduard Vrdoljak; John Fox; Simon J Cawthorn; Ashraf Patel; Claire F Snowdon; Emma Hall; Judith M Bliss; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-02       Impact factor: 41.316

8.  Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Authors:  R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss
Journal:  Lancet       Date:  2007-02-17       Impact factor: 79.321

9.  Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

Authors:  Cornelis J H van de Velde; Daniel Rea; Caroline Seynaeve; Hein Putter; Annette Hasenburg; Jean-Michel Vannetzel; Robert Paridaens; Christos Markopoulos; Yasuo Hozumi; Elysee T M Hille; Dirk G Kieback; Lina Asmar; Jan Smeets; Johan W R Nortier; Peyman Hadji; John M S Bartlett; Stephen E Jones
Journal:  Lancet       Date:  2011-01-22       Impact factor: 79.321

10.  Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

Authors:  N Zilembo; C Noberasco; E Bajetta; A Martinetti; L Mariani; S Orefice; R Buzzoni; M Di Bartolomeo; A Di Leo; A Laffranchi
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640
View more
  3 in total

Review 1.  Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.

Authors:  Yongmei Wang; Fanbo Jing; Haibo Wang
Journal:  Adv Ther       Date:  2022-01-06       Impact factor: 3.845

Review 2.  Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations.

Authors:  Priscilla A Furth
Journal:  Ann N Y Acad Sci       Date:  2012-10       Impact factor: 5.691

3.  Validation of a rapid and sensitive LC-MS/MS method for determination of exemestane and its metabolites, 17β-hydroxyexemestane and 17β-hydroxyexemestane-17-O-β-D-glucuronide: application to human pharmacokinetics study.

Authors:  Ling-Zhi Wang; Sok-Hwei Goh; Andrea Li-Ann Wong; Win-Lwin Thuya; Jie-Ying Amelia Lau; Seow-Ching Wan; Soo-Chin Lee; Paul C Ho; Boon-Cher Goh
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.